Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Glucagon-like peptide-1 receptor agonists may influence systemic inflammation beyond their glucose-lowering effects, but direct comparative evidence against other incretin-based therapies remains limited. Methods We conducted a retrospective active-comparator, new-user cohort study using routinely collected electronic health-record data from the Clinical Center of the University of Debrecen, Hungary. Patients with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist or a dipeptidyl peptidase-4 inhibitor between January 2001 and December 2024 after a 12-month washout were included. Baseline markers were summarized during months −12 to −1 and follow-up markers during months 4–12. The follow-up window was selected to reduce the influence of very early post-initiation testing while allowing assessment of a sustained biomarker difference. Propensity-score overlap weighting was used to balance demographic, metabolic, renal, cardiovascular, medication, and healthcare-observation characteristics. Results The propensity-score cohort included 1,973 patients, including 1,322 glucagon-like peptide-1 receptor agonist and 651 dipeptidyl peptidase-4 inhibitor initiators; 838 had paired C-reactive protein measurements. The adjusted geometric mean ratio for follow-up C-reactive protein was 0.80 (95% confidence interval, 0.66–0.97; P = 0.024). The neutrophil-to-lymphocyte ratio was also lower (adjusted ratio, 0.92; 95% confidence interval, 0.87–0.97; P = 0.003; q=0.007), whereas platelet count was higher by 12.12×10 9 /L (95% confidence interval, 4.65–19.59; P = 0.001; q=0.007). The C-reactive protein estimate remained similar after upper-tail winsorization, propensity-score re-estimation within the paired-CRP cohort, and patient-level bootstrap re-estimation of the propensity score. Restriction to patients with baseline CRP <10 mg/L yielded a directionally similar but less precise estimate, whereas stabilized inverse-probability-of-treatment weighting did not statistically support the association. Conclusion GLP-1 receptor agonist initiation was associated with lower follow-up CRP and NLR than DPP-4 inhibitor initiation among patients with available paired measurements in the propensity-score overlap population. However, the CRP association was attenuated in the 12-month survivor-restricted analysis and varied across other sensitivity analyses. Residual confounding by adiposity, treatment-associated weight changes, and selection related to survival and laboratory availability limit causal interpretation. The findings should be considered exploratory comparative biomarker associations rather than evidence of a direct or weight-independent anti-inflammatory effect.
Source: Frontiers in Endocrinology
Authors: Attila Nagy(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Visualization, Writing – original draft, Writing – review & editing), Amr Sayed Ghanem(Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Software, Visualization, Writing – original draft, Writing – review & editing), Battamir Ulambayar(Data curation, Writing – original draft, Writing – review & editing), Vivien Jendrek(Writing – review & editing), Ferenc Sztanek(Conceptualization, Methodology, Project administration, Supervision, Writing – original draft, Writing – review & editing)
Institution: University of Debrecen
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Keywords: type 2 diabetes, GLP-1 receptor agonists, DPP-4 inhibitors, systemic inflammation, C-reactive protein, neutrophil-to-lymphocyte ratio, platelet count, incretin-based therapy, propensity score overlap weighting, inverse probability of treatment weighting, biomarkers of inflammation, platelet activation, neutrophil activation
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234541846
